Is investing in synthetic biology worth the risk? 'Absolutely!' says Ryan Bethencourt of Berkeley Biolabs and Indie.Bio, an SOS Ventures backed biotech accelerator. From the 2014 Silicon Valley Techonomy Conference, Bethencourt explains why savvy investors need to pay attention to the latest prototypes coming down the biotech pipeline. From cellulose cotton to biodegradable batteries, the next generation of bioengineered products and processes will drastically alter manufacturing and inevitably change the international economy for commodities. TheStreet’s Olivia Zaleski sat down with the self-proclaimed, 'BioHacker' at this year’s Techonomy Conference in Silicon Valley to learn exactly what 'types of biotech' mainstream investors need to be keeping a close eye on over the coming months and years.